Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, has appointed Nadia Agopyan, Ph.D., RAC as vice president of Regulatory Affairs.  Dr. Agopyan joins the company from Kite Pharma, a subsidiary of Gilead Sciences, where she served as director of Regulatory Affairs, Global Regulatory Lead. In this role, she was responsible for overseeing the global marketing authorization and lifecycle management of the YESCARTA franchise, defining the global regulatory strategies for CAR T c...